Lee Jeong Won, Seol Ki Ho
Department of Radiation Oncology, Daegu Catholic University School of Medicine, Daegu 42472, Korea.
J Clin Med. 2021 May 19;10(10):2199. doi: 10.3390/jcm10102199.
The aim of the study was to evaluate pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors for predicting clinical outcomes after definitive concurrent chemoradiotherapy (CCRT) for cervical cancer. The cases were divided into two groups based on the values of NLR and PLR: High NLR-PLR (high value in both NLR and PLR) and Low NLR-PLR (low value in either NLR or PLR). The relationships between survival outcomes and the pretreatment NLR-PLR were investigated. Of the 148 patients enrolled in the study, 30 patients died during the median follow-up of 75 months. Based on receiver operating curves, NLR and PLR cut-off values for survival analysis were 2.34 and 148.89. The 10-year overall survival and disease-free survival rates for high NLR-PLR vs. low NLR-PLR were 63.6% vs. 86.2% ( = 0.001) and 63.3% vs. 77.5% ( = 0.026), respectively. Based on a multivariate analysis, independent predictors of overall survival were high NLR-PLR (hazard ratio [HR], 2.435; 95% confidence interval [CI], 1.106-5.361; = 0.027) and stage (HR 2.659; 95% CI, 1.146-6.613; = 0.024). Increases in both NLR and PLR are associated with poor survival. Elevation in both NLR and PLR before initiation of CCRT may be a useful biomarker for predicting clinical outcomes.
本研究的目的是评估治疗前中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）作为预测宫颈癌根治性同步放化疗（CCRT）后临床结局的预后因素。根据NLR和PLR值将病例分为两组：高NLR-PLR组（NLR和PLR均为高值）和低NLR-PLR组（NLR或PLR为低值）。研究了生存结局与治疗前NLR-PLR之间的关系。在纳入研究的148例患者中，30例患者在75个月的中位随访期内死亡。根据受试者工作曲线，生存分析的NLR和PLR临界值分别为2.34和148.89。高NLR-PLR组与低NLR-PLR组的10年总生存率和无病生存率分别为63.6%对86.2%（P=0.001）和63.3%对77.5%（P=0.026）。多因素分析显示，总生存的独立预测因素为高NLR-PLR（风险比[HR]，2.435；95%置信区间[CI]，1.106-5.361；P=0.027）和分期（HR 2.659；95%CI，1.146-6.613；P=0.024）。NLR和PLR升高均与生存不良相关。CCRT开始前NLR和PLR升高可能是预测临床结局的有用生物标志物。
